Pelu Tran is the Co-Founder and Chief Executive Officer of Ferrum Health, a San Francisco-based healthcare technology company dedicated to improving patient outcomes through the deployment of artificial intelligence (AI) in clinical settings. Under his leadership, Ferrum Health has developed a secure enterprise AI platform that enables health systems to integrate and manage AI applications, facilitating early detection of diseases and reducing diagnostic errors.
Tran’s journey into healthcare entrepreneurship began during his studies at Stanford University, where he pursued both engineering and medicine. Four months before completing his medical degree, he made the pivotal decision to leave medical school to co-found Augmedix, a company that utilized Google Glass technology to streamline medical documentation. As Chief Commercial Officer, Tran played a crucial role in expanding Augmedix to over 1,000 employees across five countries, serving more than half of the largest health systems in the United States and generating $20 million in annual revenue.
The loss of his uncle to a preventable medical error in 2018 profoundly influenced Tran’s mission to enhance diagnostic accuracy in healthcare. Recognizing the potential of AI to identify such errors, he founded Ferrum Health to bridge the gap between innovative AI solutions and their practical application in healthcare systems. The platform has since analyzed over 500,000 unique patient records, demonstrating its impact on patient safety and care quality.
Tran’s contributions to healthcare innovation have been recognized globally. He has been named a Technology Pioneer by the World Economic Forum, a Fellow of the United Nations World Summit on Innovation, and was listed in Forbes’ Healthcare 30 Under 30. Beyond his entrepreneurial endeavors, Tran shares his expertise by guest lecturing at institutions such as UC Berkeley, UCSF, and Stanford, focusing on healthcare leadership and innovation.
In 2024, Ferrum Health secured a $16 million Series A funding round, underscoring investor confidence in the company’s vision to democratize access to clinical AI technologies and enhance patient care across health systems.